E. coli
Showing 1 - 25 of 4,290
Diabetes Trial in Amsterdam (EcN Colibactin knockout, E Coli Nissle)
Not yet recruiting
- Diabetes
- EcN Colibactin knockout
- E Coli Nissle
-
Amsterdam, NetherlandsAmsterdam UMC location AMC
Apr 4, 2023
Bacterial Growth, Novel Influenza A (H1N1) Trial in Jilin (A novel electrolyzed water spray reduces numbers of bacteria E-coli
Recruiting
- Bacterial Growth
- Novel Influenza A (H1N1)
- A novel electrolyzed water spray reduces numbers of bacteria E-coli and an attenuated human flu virus on human hands
-
Jilin, Changchun, ChinaChangchun Jiahe Surgery Hospital
Apr 1, 2023
Perinatal Transmission of MDR Bacteria
Recruiting
- E. Coli Infection
- Multi-antibiotic Resistance
-
Chicago, IllinoisPrentice Women's Hospital
Nov 20, 2023
Urinary Tract Infections Trial in Nantes (Dissemination of a selective reporting for antibiotic susceptibility testing, Standard
Not yet recruiting
- Urinary Tract Infections
- Dissemination of a selective reporting for antibiotic susceptibility testing
- Standard antibiotic susceptibility testing report
-
Nantes, FranceUniversity Hospital
Sep 28, 2023
Urinary Tract Infections in Children, Secondary Prevention Trial in Finland (E. coli Nissle, Placebo control)
Recruiting
- Urinary Tract Infections in Children
- Secondary Prevention
- E. coli Nissle
- Placebo control
-
Helsinki, Finland
- +4 more
Jul 5, 2022
E. Coli Isolates From Recurrent Urinary Tract Infections
Not yet recruiting
- Urinary Tract Infections
- +2 more
- collection of bacterial strains
- (no location specified)
Apr 24, 2023
Polio Trial in Antwerpen (IMOVAX Inactivated Poliomyelitis Vaccine (IPV), dmLT (adjuvant), Bivalent oral polio vaccine (bOPV))
Completed
- Polio
- Inactivated Poliomyelitis Vaccine (IPV)
- +2 more
-
Antwerpen, Wilrijk, BelgiumUniversity of Antwerpen
Apr 5, 2022
Crohn Disease Trial in New York (Placebo, Bacteriophage preparation)
Recruiting
- Crohn Disease
- Placebo
- Bacteriophage preparation
-
New York, New YorkThe Mount Sinai Hospital
Jan 6, 2023
Advancing Age and Mortality at 30 Days in Bacteremia E. Coli
Completed
- Beta-lactamase Extended Spectrum, E. Coli, Elderly, Mortality, Risk Factor
-
Nantes, FranceCHU Nantes
Sep 20, 2021
Urinary Tract Infections Trial in United States (LBP-EC01, Placebo)
Crohn Disease Trial (Fecal Microbiota Transplantation)
Not yet recruiting
- Crohn Disease
- Fecal Microbiota Transplantation
- (no location specified)
Nov 9, 2022
E.Coli Infections, Bloodstream Infection Trial in Cincinnati (SNIPR001, Placebo)
Active, not recruiting
- E.Coli Infections
- Bloodstream Infection
- SNIPR001
- Placebo
-
Cincinnati, OhioMedpace Clinical Pharmacology
Dec 1, 2022
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma Trial
Not yet recruiting
- B Acute Lymphoblastic Leukemia
- +5 more
- Biospecimen Collection
- +4 more
- (no location specified)
Oct 28, 2022
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome Trial in Canada, United States (Infusion
Recruiting
- Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection
- Hemolytic-Uremic Syndrome
- Infusion of 200% maintenance fluids as balanced crystalloid IV solution
- Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
-
Birmingham, Alabama
- +25 more
Sep 19, 2022
Cervical Cancer, Condylomata Acuminata Trial in Nanjing (Recombinant Human Papillomavirus Nonavalent (Types
Active, not recruiting
- Cervical Cancer
- Condylomata Acuminata
- Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)
- Gardasil®9
-
Nanjing, Jiangsu, ChinaJiangsu Provincial Centre for Disease Control and Prevention
Feb 10, 2022
Cervical Intraepithelial Neoplasia, Cervical Cancer, Condylomata Acuminata Trial in Nanjing, Chengdu (Nonavalent HPV vaccine,
Active, not recruiting
- Cervical Intraepithelial Neoplasia
- +2 more
- Nonavalent HPV vaccine
- Bivalent HPV vaccine
-
Nanjing, Jiangsu, China
- +1 more
Feb 10, 2022
Developing Microbials to Fight Extended-spectrum
Active, not recruiting
- Extended Spectrum Beta Lactamases (ESBL) E. Coli
- examination of stool sample
- +2 more
-
Basel, SwitzerlandUniversity Hospital Basel, Division of Clinical Microbiology
Aug 3, 2021
Abdominal Cancer, Malignancy Trial in Pittsburgh (Lipopolysaccharide)
Recruiting
- Abdominal Cancer
- Malignancy
- Lipopolysaccharide
-
Pittsburgh, Pennsylvania
- +1 more
Feb 28, 2023
Down Syndrome, Acute Lymphoblastic Leukemia, Childhood Cancer Trial in Worldwide (Daunorubicin, Prednisolone, Vincristine)
Recruiting
- Down Syndrome
- +2 more
- Daunorubicin
- +9 more
-
Shatin, New Territories, Hong Kong
- +9 more
Sep 26, 2022
Cervical Cancer, Condylomata Acuminata Trial in Chengdu (3 doses of the Recombinant Human Papillomavirus Nonavalent (Types
Active, not recruiting
- Cervical Cancer
- Condylomata Acuminata
- 3 doses of the Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)
- 2 doses of theRecombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)
-
Chengdu, Sichuan, ChinaSichuan Provincial Centre for Disease Control and Prevention
Oct 2, 2021
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 Trial in
Not yet recruiting
- Locally Advanced Pancreatic Adenocarcinoma
- +6 more
- Biopsy
- +2 more
-
Portland, OregonOHSU Knight Cancer Institute
Apr 26, 2022
Diarrhea, Travelers Diarrhea, Infectious Diarrhea Trial in Baltimore (Travelan, Placebo)
Recruiting
- Diarrhea
- +2 more
- Travelan
- Placebo
-
Baltimore, MarylandPharmaron Clinical Pharmacology Center
Jul 5, 2023
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma Trial (Asparaginase Erwinia Chrysanthemi (recombinant))
Approved for marketing
- Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
- Asparaginase Erwinia Chrysanthemi (recombinant)
- (no location specified)
Jul 27, 2021
Collect Information About Invasive Disease Caused by
Completed
- E. Coli Infection
-
Durham, North Carolina
- +7 more
Sep 20, 2021